Safety and Efficacy of Head-lice Treatments Elimax Green Lotion and Walgreens Lice Killing Shampoo

Last updated: September 17, 2025
Sponsor: Oystershell NV
Overall Status: Active - Recruiting

Phase

N/A

Condition

Head Lice

Treatment

Elimax Green Lotion with Emogreen

Walgreens Lice Killing Shampoo

Clinical Study ID

NCT07191457
OYS011-0025
  • Ages > 6
  • All Genders

Study Summary

Compare efficacy and safety of Elimax Green Lotion Emogreen (RID SUper Max Solution) to that of Walgreens Lice Killing Shampoo against headlice in infested individuals. Involved subjects aged 6 months and older, of both genders, with a confirmed diagnosis of head lice infestation are included. Local and global tolerability, skin and eye irritation are monitored throughout the study. Any adverse events will be monitored and recorded.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Gender: male / female.

  • Female subjects with childbearing potential who test negative for pregnancy andagree to use a reliable method of birth control (as described in section7.8) orremain

  • Age ≥ 6 months of age at the time of enrollment.

  • Subject must have an active head lice infestation defined as at least 5 live lice (adults and/or nymphs) and 5 live nits based on magnified observations, present onthe scalp and/or hair, as determined by a trained evaluator.

  • Subject is in good general health based on medical history.

  • Following application per designated product timeline shampoo hair using Johnson'sbaby shampoo (See figure 4 for shampoo image) to rinse out the product according tothe study product its IFU. Subject agrees not to additionally shampoo, wash, orrinse their hair or scalp for 24-hours post treatment.

  • The subject agrees not to cut or chemically treat their hair while participating inthe study.

  • Subject agrees to follow all study instructions, including attending all follow-upappointments.

  • Agree to not use any other anti-lice treatment or medicated hair grooming productsfor the duration of the study (through Day 10 visit).

  • The parent or legal guardian of a child must be willing to have other family membersscreened for head lice. If other household members are found to have head lice andare eligible, they must be either enrolled in the study OR receive the standard ofcare at the site and in the same manner as study participants.

  • Have a single place of residence or agree to remain at the current residence for theduration of the study.

  • The subject or his/her parent/legal guardian (from age 12-17), must give writteninformed consent, after having been informed orally and by written text about thebenefits and potential risks of the trial, as well as information regarding theinsurance, taken out to cover the subjects participating in the study. A caregivermust sign an informed consent agreement for children not old enough to do so.Children aged 6-11 years of age will be administered a child's assent form. Subjector his/her parent/legal guardian must be capable of understanding and providingwritten informed consent.

Exclusion

Exclusion Criteria:

  • Application of any form of head lice treatment, whether prescription orover-thecounter (OTC), or home remedy for 14 days prior to their screening visit (Visit

  • Application of any topical medication of any kind on the hair or scalp for a periodof 48 hours prior to the screening visit.

  • Use of systemic or topical drugs or medications, including systemic antibiotics,which in the opinion of the investigative personnel may interfere with the studyresults.

  • Known skin allergies, multiple drug allergies or multiple allergies to cosmeticproducts.

  • History of allergy or hypersensitivity to active ingredients, or constituents of thetest products.

  • Subject with any visible skin/scalp condition at the treatment site which, in theopinion of the investigative personnel, will interfere with the evaluation of thetest product.

  • Subjects with chronic scalp disorder.

  • Subject or his/her legal guardian who, in the opinion of the investigativepersonnel, do not understand the subject requirements for study participationsand/or may be likely to exhibit poor compliance with the required visits.

  • Females who are pregnant or nursing.

  • Hair longer than waist length.

  • Subject suspected or known not to follow instructions

  • Previous participation in this study or participation in any other investigationaltrial within the preceding 14 days.

  • The subject is directly affiliated to the investigator site personnel and/or theirimmediate families. Immediate family is defined as a spouse, parent, child, orsibling, whether biological or legally adopted.

  • The subject is an Oystershell employee or is an employee of a third-partyorganizations involved in the study.

  • Exclude families with 4 or more household members.

  • People with dreadlocks or clip in hair that cannot be removed or a person who doesnot want to remove these.

  • Hair that is too difficult to work with, assessed by the study staff.

  • Families excluded where lice exist however family member declines enrollment in thestudy.

  • Subjects who are receiving, or are expected to receive, any antibiotic therapyduring the study period will be excluded.

  • No more than one working subject per household may be excluded from evaluation if heis assessed as being lice by himself or caregiver. Only working male can be excludedfrom evaluation if individual is bald or hair no longer than half inch and deemedlice free by himself or another adult.

  • All household members of the subject, other than excluded male adult, must bescreened for head lice by a licenced head lice professional. If additional householdmembers are found to have head lice and meet the study criteria, they will bereferred to LSRN Research and enrolled in study. If a household member declinesenrollment, all family members will be excluded from the study.

Study Design

Total Participants: 86
Treatment Group(s): 2
Primary Treatment: Elimax Green Lotion with Emogreen
Phase:
Study Start date:
October 02, 2025
Estimated Completion Date:
April 01, 2026

Study Description

The primary objective of this study is to evaluate and compare efficacy and safety of X92001752 Emogreen with Walgreens Lice Killing Shampoo (Piperonyl Butoxide (4%), Pyrethrum Extract (Equivalent to 0.33% Pyrethrins)) against head lice (Pediculus capitis) in infested individuals. More specifically, the present study aims to confirm the clinical performance and safety of head lice treatment product: Elimax Green Lotion with Emogreen L15® (INCI C15-19 alkane) as main ingredient (X92001752). This product works in the same way as Elimax Green Lotion with Hemisqualane® (INCI hydrogenated farnesene) namely, by physically suffocating and dehydrating lice and their nits due to the presence of a bio-alkane and beeswax. They are generally combined with a lice comb in a procedure pack. Elimax Green Lotion is classified as Class I medical devices in Europe. In the US, the products are packaged with a lice comb and registered as a Lice Removal Kit, in accordance with 21 CFR 880.5960, which is 510(k)-exempt.

In line with US regulations, the guidelines for clinical trials of medical devices must be adhered to. The study will involve subjects aged 6 months and older, of both genders, with a confirmed diagnosis of head lice infestation. To support safety assessments, local and global tolerability, skin and ocular irritation, and adverse events (AEs) will be monitored and recorded.

Connect with a study center

  • LSRN Research

    Enid 4535961, Oklahoma 4544379 73701
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.